Riggioni, CarmenComberiati, PasqualeGiovannini, MattiaAgache, IoanaAkdis, MuebeccelAlves-Correia, MagnaAnto, Josep M.2021-01-142021-01-142020Riggioni, C, Comberiati, P, Giovannini, M, et al. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy. 2021; 75: 2503– 2541.0105-45381398-9995https://doi.org/10.1111/all.14449https://hdl.handle.net/20.500.12587/12634Jimenez-Saiz, Rodrigo/0000-0002-0606-3251; O'Mahony, Liam/0000-0003-4705-3583; Comberiati, Pasquale/0000-0001-5209-9733; O'Hehir, Robyn/0000-0002-3489-7595; de las Vecillas Sanchez, Leticia/0000-0003-4969-5678; RIGGIONI, CARMEN/0000-0002-8745-0228; Correia, Magna/0000-0002-7676-5558; AZKUR, DILEK/0000-0002-4396-9087In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID-19). This disease, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), has developed into a pandemic. To date, it has resulted in similar to 9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID-19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence-based medical advice on SARS-CoV-2 and COVID-19. Although the majority of the patients show a very mild, self-limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID-19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a "cytokine storm" leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID-19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID-19-related topics should be based on more coordinated high-quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS-CoV-2, COVID-19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID-19 and allergic disease.eninfo:eu-repo/semantics/openAccessallergycoronavirus disease 2019COVID-19SARS-CoV-2severe acute respiratory syndrome-related coronavirus 2Review Article75102503254110.1111/all.144492-s2.0-8508824792832535955Q1WOS:000550399700001Q1